{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-095063","form_type":"8-K","ticker":"TCRX","cik":"0001783328","company_name":"TScan Therapeutics, Inc.","filed_at":"2024-08-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.508924+00:00","generated_at":"2026-05-31T10:06:09.776884+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"TScan Q2 net loss $31.7M; revenue falls to $0.5M; RMAT designation for lead candidates","bullets":["Revenue $0.5M, down from $3.1M in Q2 2023, primarily due to Amgen collaboration timing.","Net loss $31.7M vs $24.0M in Q2 2023; R&D expenses increased to $26.9M from $21.2M.","Cash, equivalents, and marketable securities $297.7M (plus $5M restricted); funds into Q4 2026.","FDA granted RMAT designation for TSC-100 and TSC-101 for AML, ALL, MDS post-HCT.","On track to report one-year heme data and initial solid tumor data by end of 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-095063","json":"https://secwatch.observer/filing/0000950170-24-095063.json","markdown":"https://secwatch.observer/filing/0000950170-24-095063.md","text":"https://secwatch.observer/filing/0000950170-24-095063.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1783328/000095017024095063/0000950170-24-095063-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1783328/000095017024095063/tcrx-20240812.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T10:06:09.776884+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}